Navigation Links
Latest advances in DNA sequencing highlighted at DOE Joint Genome Institute User Meeting

Four hundred researchers tapping the massive flow of DNA sequence information will gather March 28-30 to share their recent developments at the 2nd Annual U.S. Department of Energy Joint Genome Institute (DOE JGI) User Meeting. DOE JGI is the world's only user facility dedicated to making high-throughput DNA sequencing available to a diverse research community and individual investigators who otherwise would not have access to such a resource to advance the frontiers of their disciplines. The meeting will be held in the California Ballroom at the Walnut Creek Marriott, 2355 North Main Street.

Highlights of the three-day event include:

  • Search for Superior Biofuels
Larry Wackett, University of Minnesota

  • Engineering Microbes for Production of Low-Cost, Effective, Anti-Malarial Drugs
Jay Keasling, Lawrence Berkeley National Laboratory

  • A Genomic Encyclopedia for Bacteria and Archaea
Jonathan Eisen, University of California, Davis

  • Explorations of the Human Microbiome
David Relman, Stanford University

  • New Amplification and Cloning Tools
David Mead, Lucigen Corporation

  • Integrated Microbial Genomes (IMG) data management system workshop

  • Tours of the DOE JGI Production Genomics Facility

The complete agenda, registration, and other details may be found at: http://www.jgi.doe.gov/meetings/usermtg07/index.html
'"/>

Source:DOE/Joint Genome Institute


Page: 1

Related biology news :

1. Slow-frozen people? Latest research supports possibility of cyropreservation
2. Research advances quest for HIV-1 vaccine
3. Inexpensive, mass-produced genes core of synthetic biology advances at UH
4. Study of genomic DNA leads to new advances in cancer diagnostics
5. Scientists create digital bacteria to forge advances in biomedical research
6. Discovery of new molecular tools for biosynthesis could lead to advances in use of pectin
7. Gene therapy for hereditary lung disease advances
8. MITs molecular sieve advances protein research
9. Nanotechnology propels advances in regenerative medicine research
10. MIT bioengineer advances survival, promise of adult stem cells
11. Color-blind method opens new doors in DNA sequencing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: